Navigation Links
Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
Date:9/13/2010

RESEARCH TRIANGLE PARK, N.C., Sept. 13 /PRNewswire/ -- Max Neeman International, a leading Indian CRO, announces the expansion of therapeutic focused device clinical trial services in India. Max Neeman has formed an experienced and world class team of medical device experts specializing in carrying out cardiac device trials – therapeutic, diagnostic and surgical. Coronary artherectomy, cardiac stents, aneurysm, mitral valve regurgitation and acute coronary syndrome form 90% of the total device trial experience. These are multicentric global trials with patients as high as 300.  Along with prior experience of conducting device trials, the specialized Max Neeman team and services adds an enhanced level of company expertise in conducting simple to complex device studies.  Max Neeman also has medical device operations and regulatory experience in various other device therapeutic areas as well including CNS and Ophthalmology.

India is emerging as a destination of choice for medical device development and conducting device trials as the market for percutaneous coronary interventions has expanded.  India's device market is currently valued at US $1.7 Billion and projected to grow at the rate of 23% annually.  Benefits which have accelerated outsourcing of device trials to India include: shortened product development cycle, faster time to market (by approximately 30% due to faster patient recruitment) and testing resulting in significant cost savings of about 40-50%.  Max Neeman International conducts device studies for small to large device firms across the globe delivering high quality results at a lower cost resulting in high client satisfaction.  

About Max Neeman International
Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in over 22 cities with 6 regional offices.  Contact Donald Swankie, Vice President of Business Development via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  For more information please visit www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
2. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
3. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
4. PRA Internationals Drug Safety Experts to Speak at Safety Congress
5. Biosystems International Merges With Microbiochips
6. Medizone International Files For Additional Bio-Terrorism Countermeasures Patent Protection
7. International Isotopes Inc. Announces Completion of a Licensing and Permitting Assistance Agreement with URENCO USA
8. Dyadic International and EnGen Bio to Present at Rodman & Renshaw Annual Global Investment Conference
9. Dyadic International Raises Additional $1 Million to Complete $4 Million Convertible Note Offering
10. /C O R R E C T I O N - Mindray Medical International Limited /
11. Ellman International Announces Executive Team Hire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), ... sale and distribution of the AeroForm® Tissue Expander System, ... commercial roll-out in the United States ... hundred (100) medical institutions and health systems, located throughout ... alternative for women who choose reconstructive surgery following a ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... Guide to ... , No matter on which side of the Atlantic devicemakers do business, ... regulations they have to follow. , In addition to the full text of the ...
(Date:6/28/2017)... ... June 28, 2017 , ... The Wharton School’s ... mid-market executives as a kick-off to the fifth annual CEO Connection Mid-Market Convention. ... the University of Pennsylvania campus, followed by the two-day convention, which will target ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, ... regions access to insurance assistance and financial planning services, is announcing the commencement ... families in the region facing financial crisis. , Matthew 25: Ministries (M25M) is ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands that ... they can trust the sponsor to pay them correctly and on time. As the ... establish payment strategies that encourage sites to work on their studies. , At a ...
(Date:6/27/2017)... , ... June 27, 2017 , ... From June 20-22, ... three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... how to connect with today’s savvy consumer, and the latest in hearing technology. ...
Breaking Medicine News(10 mins):